Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Shares of 2seventy bio took flight Tuesday after the biotechnology company agreed to be acquired by partner Bristol Myers Squibb. Bristol Myers is paying $5 a share in cash for 2seventy, a 79% premium ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. Bristol Myers has agreed to buy out ...

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

The European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...

PRINCETON, N.J., March 13, 2025--Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025 PRINCETON, N.J., March 08, 2025--Bristol Myers Squibb Presents Late-Breaking Data ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...